CTL response to Mycobacterium tuberculosis: identification of an immunogenic epitope in the 19-kDa lipoprotein.
The successful resolution of infection with Mycobacterium tuberculosis (M.tb) is believed to involve the induction of CTLs that are capable of killing cells harboring this pathogen, although little information is known about the MHC restriction or fine specificity of such CTLs. In this study, we used knowledge of the HLA-A*0201-binding motif and an immunofluorescence-based peptide-binding assay to screen for potential HLA-A*0201-binding epitopes contained in the 19-kDa lipoprotein of M.tb (M.tb19). CD8+ T cells derived from HLA-A*0201+ patients with active tuberculosis (TB) as well as tuberculin skin test-positive individuals who had no history of TB were used as effector cells to determine whether these epitopes are recognized by in vivo-primed CTLs. An in vitro vaccination system using HLA-A*0201+ dendritic cells (DCs) as APCs was used to determine whether these epitopes can sensitize naive CD8+ T cells in vitro, leading to the generation of Ag-specific CTLs. The results show that an HLA-A*0201-binding peptide comprised of residues 88 to 97 of M.tb19 (P88-97) is recognized by circulating CD8+ CTLs from both healthy tuberculin skin test-positive individuals and patients with active TB but not by tuberculin skin test-negative subjects. Moreover, dendritic cells pulsed with this peptide induced class I MHC-restricted CTLs from the T cells of healthy unsensitized persons. Finally, CTL lines that were specific for P88-97 were shown to lyse autologous monocytes that had been infected acutely with the H37Ra strain of M.tb. These results demonstrate that M.tb19 elicits HLA class I-restricted CTLs in vitro and in vivo that recognize endogenously processed Ag. Epitopes of the type identified here may prove useful in the design of an M.tb vaccine.
Mohagheghpour
N
N
Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco 94115, USA. nahid@cooper.cpmc.org
Gammon
D
D
Kawamura
L M
LM
van Vollenhoven
A
A
Benike
C J
CJ
Engleman
E G
EG
D000483:Alleles; D001426:Bacterial Proteins / Q000096:biosynthesis / Q000276:immunology* / Q000378:metabolism; D003602:Cytotoxicity, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000096:biosynthesis / Q000302:isolation & purification* / Q000378:metabolism; D015234:HLA-A Antigens / Q000378:metabolism; D006801:Humans; D016056:Immunodominant Epitopes / Q000096:biosynthesis / Q000302:isolation & purification* / Q000378:metabolism; D008074:Lipoproteins / Q000276:immunology* / Q000378:metabolism; D008213:Lymphocyte Activation; D008970:Molecular Weight; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology / Q000302:isolation & purification / Q000378:metabolism; D011485:Protein Binding / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
C087864:19 kDa antigen, Mycobacterium; D001426:Bacterial Proteins; D018984:Epitopes, T-Lymphocyte; D015234:HLA-A Antigens; D016056:Immunodominant Epitopes; D008074:Lipoproteins; D010446:Peptide Fragments